Cost-effectiveness of patient-matched pre- and on-treatment biomarkers in cancer therapy response prediction
Giovanni Tramonti
Cancer
Background: The development of new biomarkers allows for the accurate prediction of breast cancer therapy response in the neoadjuvant setting. The implementation of these tools in routine NHS operations could have the potential for better clinical outcomes and a more cost-effective use of resources.
Read More